ImmunoGen Reports Recent Progress and Second Quarter 2018 Operating Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/8/2026
- US stock futures tumble as Trump says Iran deal is 'over', oil climbs
- Oil jumps over 6% to two-week high after Trump says deal with Iran 'over'
- Citi says SpaceX stock has path to $900+ valuation. Here’s how
- Tesla stock target lifted at RBC on potential SpaceX merger
- Short squeezes more likely than widespread selling: Citi
- Morgan Stanley Reiterates Overweight Rating on Rocket Lab USA (RKLB), Bull Case Raised to $293
- Fiserv president resigns, interim leaders named for financial unit
- Nasdaq sinks as AI worries hit chipmakers
- Amazon launches bond sale seeking at least $25 billion
- Raymond James Starts SpaceX (SPCX) at Strong Buy, PT Street High $800
Immunogen (IMGN) Misses Q2 EPS by 2c, Miss on Revenues
July 27, 2018 6:37 AM EDTImmunogen (NASDAQ: IMGN) reported Q2 EPS of ($0.31), $0.02 worse than the analyst estimate of ($0.29). Revenue for the quarter came in at $9.29 million versus the consensus estimate of $13.92 million.
During the second quarter, we made significant progress with mirvetuximab soravtansine, highlighted by FDA Fast Track designation for the treatment of platinum-resistant ovarian cancer, and completion of enrollment in our... More
